Equillium announces acceptance of late-breaking abstract for oral presentation of interim data from equate study in acute gvhd at the 2021 tct meetings digital experience

La jolla, calif., jan. 22, 2021 (globe newswire) -- equillium, inc. (nasdaq: eq) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the phase 1b/2 equate study of itolizumab in acute graft-versus-host disease (agvhd) has been accepted as a late-breaking oral presentation at the 2021 tct meetings digital experience, being held february 8-12, 2021.
EQ Ratings Summary
EQ Quant Ranking